There is growing pressure for robust and economically scalable viral-vector manufacturing technologies.
Mercedes Segura Gally
Advertisement
Mercedes Segura Gally is vice-president of Vector Process Development at ElevateBio.
Articles by Mercedes Segura Gally
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
